NasdaqGM - Delayed Quote • USD
Coherus BioSciences, Inc. (CHRS)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:09 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 4 | 5 |
| Avg. Estimate | -0.24 | -0.22 | -0.78 | 0.04 |
| Low Estimate | -0.37 | -0.33 | -0.96 | -0.57 |
| High Estimate | -0.05 | -0.04 | -0.41 | 0.68 |
| Year Ago EPS | -0.75 | -0.38 | -1.98 | -0.78 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 5 | 7 | 7 |
| Avg. Estimate | 80.25M | 53.68M | 261.64M | 357.26M |
| Low Estimate | 47.07M | 49.56M | 206.49M | 279.91M |
| High Estimate | 102M | 68M | 324M | 513.75M |
| Year Ago Sales | 47.44M | -- | 257.24M | 261.64M |
| Sales Growth (year/est) | 69.20% | -- | 1.70% | 36.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.57 | -0.48 | -0.27 | -0.12 |
| EPS Actual | -0.75 | -0.38 | -0.27 | -0.62 |
| Difference | -0.18 | 0.1 | 0 | -0.5 |
| Surprise % | -31.60% | 20.80% | 0.00% | -416.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.24 | -0.22 | -0.78 | 0.04 |
| 7 Days Ago | -0.24 | -0.22 | -0.78 | 0.04 |
| 30 Days Ago | -0.23 | -0.22 | -0.72 | 0.07 |
| 60 Days Ago | -0.23 | -0.18 | -0.25 | 0.01 |
| 90 Days Ago | -0.2 | -0.14 | -0.07 | 0.26 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CHRS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 68.00% | -- | -- | 5.40% |
| Next Qtr. | 42.10% | -- | -- | 10.90% |
| Current Year | 60.60% | -- | -- | 4.50% |
| Next Year | 105.10% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -25.10% | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/14/2024 |
| Maintains | Baird: Outperform to Outperform | 1/23/2024 |
| Maintains | Truist Securities: Buy to Buy | 1/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/27/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/7/2023 |
Related Tickers
ARQT Arcutis Biotherapeutics, Inc.
8.47
-1.40%
AGEN Agenus Inc.
11.69
+40.84%
ADCT ADC Therapeutics SA
4.3400
-2.25%
FGEN FibroGen, Inc.
1.0400
+1.96%
CYTK Cytokinetics, Incorporated
65.34
+0.83%
MCRB Seres Therapeutics, Inc.
0.8250
+11.08%
OCUL Ocular Therapeutix, Inc.
4.7450
+12.98%
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
TGTX TG Therapeutics, Inc.
13.47
-3.16%
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%